And the market was wrong then given the IP of HER-Vaxx wasn't even close to Ph2 clinical trial completion so what makes you think the market is now right??? Like I told you then, the MC was too high for a biotech start-up at that development stage and you tried to argue with me as you were clearly ramping and trading the stock, well look who is correct now lol.
How much do you value the MC for VAXINIA, OASIS and Azer-Cel all close to similar development stage for HER-Vaxx given the solid and liquid cancer treatment market is much bigger than Chemotherapy???? Probably easily worth $3.5B
If you are trader then IMU has been and probably will continue to be very difficult to predict and trade as there's a big disconnect between the fundamental but if you are investing for the big return then clinical trials are and will always the main event for biotech start-up stock.
(20min delay)